Wilson W R, Siegel R S, Harisiadis L A, Davis D O, Nguyen H H, Bank W O
Division of Hematology and Oncology, George Washington University Medical Center, 2150 Pennsylvania Ave, NW, Suite 3-428, Washington, DC 20037, USA.
Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):809-12.
To assess the effectiveness of a protocol consisting of 4 cycles of high-dose intra-arterial cisplatin infusions followed by radiation therapy for improving chemotherapy response rates, organ preservation, and survival in patients with advanced-stage untreated and previously treated squamous cell carcinoma of the head and neck.
A prospective study of sequentially enrolled patients treated in an academic medical center. The Kaplan-Meier method was used for survival analysis.
Fifty-eight nonpregnant adults, 18 years of age or older, with measurable untreated or recurrent advanced biopsy-proven squamous cell carcinoma of the head and neck.
Response rate to targeted intra-arterial cisplatin infusions, organ preservation, and survival.
Fifty-eight patients (44 men and 14 women) were followed up for at least 2 years (median duration of follow-up, 27 months). Twenty-nine (67%) of the 43 previously untreated patients had a complete response to intra-arterial cisplatin therapy. Of the untreated patients, 28 are alive and disease free after a median follow-up time of 30 months. Five of the patients with recurrent disease had a complete response to intra-arterial cisplatin therapy. There were 4 survivors after a median follow-up time of 17.5 months. Of note, there were no deaths or serious complications related to the treatment in either group.
High-dose intra-arterial cisplatin therapy provides a high complete and partial response rate (91%). The combination of high-dose intra-arterial cisplatin and radiation therapy is effective in improving survival and organ preservation rates in patients with previously untreated, advanced squamous cell carcinoma of the head and neck. This treatment protocol is much less effective for recurrent disease.
评估由4个周期大剂量动脉内顺铂输注后进行放射治疗组成的方案,对改善晚期未经治疗及先前接受过治疗的头颈部鳞状细胞癌患者的化疗缓解率、器官保留率和生存率的有效性。
一项在学术医疗中心对序贯入组患者进行的前瞻性研究。采用Kaplan-Meier方法进行生存分析。
58名非妊娠成年人,年龄18岁及以上,患有可测量的未经治疗或复发性晚期经活检证实的头颈部鳞状细胞癌。
对靶向动脉内顺铂输注的缓解率、器官保留率和生存率。
58名患者(44名男性和14名女性)接受了至少2年的随访(中位随访时间为27个月)。43名先前未经治疗的患者中有29名(67%)对动脉内顺铂治疗完全缓解。在未经治疗的患者中,中位随访30个月后,28名患者存活且无疾病。5名复发性疾病患者对动脉内顺铂治疗完全缓解。中位随访17.5个月后有4名幸存者。值得注意的是,两组中均无与治疗相关的死亡或严重并发症。
大剂量动脉内顺铂治疗可提供较高的完全缓解率和部分缓解率(91%)。大剂量动脉内顺铂与放射治疗联合使用,对改善先前未经治疗的晚期头颈部鳞状细胞癌患者的生存率和器官保留率有效。该治疗方案对复发性疾病的效果要差得多。